Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
Santos R, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, Scemama M, Manvelian G, Garon G, Daniels S. Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins. European Heart Journal 2023, 44: ehad655.2809. DOI: 10.1093/eurheartj/ehad655.2809.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Safety of alirocumabKey secondary endpointHeterozygous familial hypercholesterolaemiaWeek 24Secondary endpointsPediatric patientsLipid parametersFamilial hypercholesterolaemiaTreatment periodTreatment groupsInternational phase 3 trialConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Atherogenic lipid parametersEfficacy of alirocumabMean baseline LDLOpen-label periodPhase 3 trialLDL cholesterol levelsSignificant treatment differencesAlirocumab treatmentBaseline LDLPlacebo Q2WWeek 104